These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 29721583)
21. Amino acid and glucose metabolism in fed-batch CHO cell culture affects antibody production and glycosylation. Fan Y; Jimenez Del Val I; Müller C; Wagtberg Sen J; Rasmussen SK; Kontoravdi C; Weilguny D; Andersen MR Biotechnol Bioeng; 2015 Mar; 112(3):521-35. PubMed ID: 25220616 [TBL] [Abstract][Full Text] [Related]
22. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality. Meuwly F; Weber U; Ziegler T; Gervais A; Mastrangeli R; Crisci C; Rossi M; Bernard A; von Stockar U; Kadouri A J Biotechnol; 2006 May; 123(1):106-16. PubMed ID: 16324762 [TBL] [Abstract][Full Text] [Related]
23. Development of hyper osmotic resistant CHO host cells for enhanced antibody production. Kamachi Y; Omasa T J Biosci Bioeng; 2018 Apr; 125(4):470-478. PubMed ID: 29233458 [TBL] [Abstract][Full Text] [Related]
24. Factors affecting the quality of therapeutic proteins in recombinant Chinese hamster ovary cell culture. Ha TK; Kim D; Kim CL; Grav LM; Lee GM Biotechnol Adv; 2022; 54():107831. PubMed ID: 34480988 [TBL] [Abstract][Full Text] [Related]
25. Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production. Dizon-Maspat J; Bourret J; D'Agostini A; Li F Biotechnol Bioeng; 2012 Apr; 109(4):962-70. PubMed ID: 22094920 [TBL] [Abstract][Full Text] [Related]
26. An automated high inoculation density fed-batch bioreactor, enabled through N-1 perfusion, accommodates clonal diversity and doubles titers. Olin M; Wolnick N; Crittenden H; Quach A; Russell B; Hendrick S; Armstrong J; Webster T; Hadley B; Dickson M; Hodgkins J; Busa K; Connolly R; Downey B Biotechnol Prog; 2024; 40(2):e3410. PubMed ID: 38013663 [TBL] [Abstract][Full Text] [Related]
36. Bench-Scale Stirred-Tank Bioreactor for Recombinant Protein Production in Chinese Hamster Ovary (CHO) Cells in Suspension. Monteil D; Kuan J Methods Mol Biol; 2024; 2810():235-247. PubMed ID: 38926283 [TBL] [Abstract][Full Text] [Related]
37. Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies. Barnard GC; Zhou M; Shen A; Yuk IH; Laird MW Biotechnol Prog; 2024; 40(1):e3399. PubMed ID: 37874920 [TBL] [Abstract][Full Text] [Related]
38. Chemometrics and in-line near infrared spectroscopic monitoring of a biopharmaceutical Chinese hamster ovary cell culture: prediction of multiple cultivation variables. Clavaud M; Roggo Y; Von Daeniken R; Liebler A; Schwabe JO Talanta; 2013 Jul; 111():28-38. PubMed ID: 23622522 [TBL] [Abstract][Full Text] [Related]
39. Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO pools. Rajendra Y; Balasubramanian S; Peery RB; Swartling JR; McCracken NA; Norris DL; Frye CC; Barnard GC Biotechnol Prog; 2017 Mar; 33(2):534-540. PubMed ID: 28188692 [TBL] [Abstract][Full Text] [Related]
40. Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events. Fratz-Berilla EJ; Angart P; Graham RJ; Powers DN; Mohammad A; Kohnhorst C; Faison T; Velugula-Yellela SR; Trunfio N; Agarabi C Biotechnol Bioeng; 2020 Sep; 117(9):2802-2815. PubMed ID: 32436993 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]